Official announcements from relevant health authorities worldwide

Eli Lilly's Donanemab Claimed to Prevent Alzheimer's Despite Limited Data

Oct 13, 2024, 10:02 AM

In a December 2023 meeting with Conservative minister Victoria Atkins, Eli Lilly's CEO David Ricks stated that the company's new drug, donanemab, has the potential to prevent Alzheimer's by treating individuals before symptoms develop. The pharmaceutical company communicated this to the UK health secretary, emphasizing the drug's potential as a preventive treatment. However, an Oxford economist has expressed concerns that Britain might miss the opportunity to fully capitalize on this medical breakthrough. Despite these claims, there is limited data to support the drug's efficacy, as revealed through freedom of information requests.